Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market Thursday that its third quarter revenues rose sharply year over year on increased test volume.

The San Diego-based maker of cancer biomarker assays reported total revenues of $164,856 for the three months ended Sept. 30, up from $10,274 for the third quarter of 2014. It said that it accessioned 482 commercial cases during the quarter, nearly five times the 96 commercial cases for the third quarter of 2014.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.